2026 SNO Annual Meeting Late-Breaking Abstract Guidelines

Placeholder Deadline: Tuesday, May 26, 2026, at 11:59 pm ET
Final Deadline: Friday, September 4, 2026, at 5:00 pm ET

 

SNO recognizes that some rapidly advancing studies and investigations may include results that are not yet available at the abstract submission deadline of May 26, 2026. Therefore, SNO will allow authors to submit late-breaking research from late-phase clinical trials for consideration at the 2026 SNO Annual Meeting.

Late-Breaking submissions must follow the guidelines outlined below, and a “placeholder abstract” must be submitted by the initial May 26, 2026, deadline. Placeholder abstracts not submitted by this date will not be eligible for late-breaking submission at a later time. Only late-phase clinical trials with interim or final analyses may be submitted as Late-Breaking abstracts. Other abstracts may be rejected.

 

Late-Breaking Submission Fee: A $125 USD non-refundable submission fee will be charged per late-breaking abstract submitted. Payment is due at the time of submission. Checks, wire transfers, and purchase orders will not be accepted. 

Please note that only a limited number of abstracts from the Late-Breaking category will be selected for presentation at the SNO Annual Meeting in Philadelphia, Pennsylvania. Authors should note the following important information before submitting a Late-Breaking Abstract:

  • Late-breaking abstract submitters MUST use the late-breaking link to submit a late-breaking abstract. Abstracts submitted as Late Breaking using the regular or LMIC submission will be withdrawn and not considered for presentation.
  • An abstract placeholder must be submitted by the May 26, 2026, deadline.
  • Late-breaking abstracts must be a late phase clinical trial following interim or final analysis. 
  • Abstracts accepted for late-breaking presentation will not be included in the regular abstract supplement to the journal Neuro-Oncology and will be published electronically on the day of presentation.
  • Late-breaking abstracts will not be considered for awards.
  • A $125 (USD) non-refundable fee must be paid upon submission. Abstracts without payment will be withdrawn
  • The Scientific Planning Committee will determine the final presentation format of all accepted late-breaking abstracts.


Please note: This category is not intended to offer a second deadline for regular abstract submissions.

To be considered for a late-breaking abstract status, the submitting author must:

  • Submit the abstract using the designated late-breaking submission link.
  • Select the appropriate late-breaking category:
  • Clinical Trials: Immunologic
  • Clinical Trials: Non-Immunologic.
  • Provide a late-phase clinical trial abstract placeholder including objectives and methods but excluding results and conclusions. Include any information that supports the potential for late-breaking impact and the planned date of analysis. The placeholder submission deadline is Tuesday, May 26, 2026, at 11:59 PM ET.
  • Submit a non-refundable $125 (USD) submission fee that must be paid at the time of placeholder submission. Again, abstracts without payment will be withdrawn.
  • Submit a finalized Late-Breaking abstract with results and conclusions by Friday, September 4, 2026, at 5:00 PM ET. Abstracts not updated by this deadline will be automatically rejected.